MedTrace Logo

Rosmalip® for Cancer Infections Prevention

NCT05080920 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2023-09-21

No results posted yet for this study

Summary

This study is designed to assess the safety and efficacy of Rosmalip® nutritional supplement compared to placebo in subjects with solid cancer for the prevention of infections including COVID-19.

Conditions

Interventions

DIETARY_SUPPLEMENT

Rosmalip®

Nutritional Supplement+Usual Care

OTHER

Placebo

Placebo+Usual Care

Sponsors & Collaborators

  • IMDEA Food

    collaborator OTHER

  • Universidad Autonoma de Madrid

    collaborator OTHER

  • Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares

    lead OTHER

Principal Investigators

  • Enrique Casado Sáenz, MD · Servicio de Oncología. Hospital Infanta Sofía

  • Ana Ramírez de Molina, PhD · IMDEA Food

  • Guillermo Reglero Rada, PhD · CIAL_UAM_CSIC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05080920 on ClinicalTrials.gov